Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Receivables (2021 - 2025)

Core Scientific has reported Receivables over the past 5 years, most recently at $1.0 million for Q1 2025.

  • Quarterly results put Receivables at $1.0 million for Q1 2025, down 8.04% from a year ago — trailing twelve months through Mar 2025 was $1.0 million (down 8.04% YoY), and the annual figure for FY2024 was $1.0 million, up 2.4%.
  • Receivables reached $1.0 million in Q1 2025 per CORZ's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Receivables topped out at $6.2 million in Q3 2024 and bottomed at $46000.0 in Q4 2022.
  • Median Receivables over the past 5 years was $1.1 million (2023), compared with a mean of $1.9 million.
  • The largest annual shift saw Receivables plummeted 97.27% in 2022 before it skyrocketed 2076.09% in 2023.
  • Over 5 years, Receivables stood at $1.7 million in 2021, then tumbled by 97.27% to $46000.0 in 2022, then surged by 2076.09% to $1.0 million in 2023, then grew by 2.4% to $1.0 million in 2024, then decreased by 0.68% to $1.0 million in 2025.
  • Business Quant data shows Receivables for CORZ at $1.0 million in Q1 2025, $1.0 million in Q4 2024, and $6.2 million in Q3 2024.